Cargando…

Stem Cell-based Products in Medicine: FDA Regulatory Considerations

Detalles Bibliográficos
Autor principal:	Bauer, Steven R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2004
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149600/ http://dx.doi.org/10.1016/B978-012436643-5/50163-2

Ejemplares similares

International regulatory considerations pertaining to the development of stem cell-based veterinary medicinal products
por: Jeon, Byung-Suk, et al.
Publicado: (2021)

USING REAL-WORLD EVIDENCE TO SUPPORT THE FDA REGULATORY APPROVAL: METHODOLOGICAL CONSIDERATIONS
por: Lu, Kevin, et al.
Publicado: (2022)

Testing of Adenoviral Vector Gene Transfer Products: FDA Expectations
por: Bauer, Steven R., et al.
Publicado: (2002)

S-11-02 Regulatory considerations for non-clinical studies for COVID-19 vaccines: US FDA perspective
por: Wrzesinski, C.
Publicado: (2022)

The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
por: Wittes, Janet, et al.
Publicado: (2015)

The FDA initiatives for personalized medicine
por: Wolfe, Olive Joy
Publicado: (2014)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)
por: Seo, Yurim, et al.
Publicado: (2020)

The Use of External Controls in FDA Regulatory Decision Making
por: Jahanshahi, Mahta, et al.
Publicado: (2021)

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

The 2014 FDA assessment of commercial fish: practical considerations for improved dietary guidance
por: McGuire, Jennifer, et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Regulations and guidelines governing stem cell based products: Clinical considerations
por: George, Bobby
Publicado: (2011)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
por: Mol, Peter G. M., et al.
Publicado: (2018)

Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerations
por: Goedecke, Thomas, et al.
Publicado: (2017)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot
por: Gao, Ya Grace, et al.
Publicado: (2022)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

Considerations for the clinical use of stem cells in genitourinary regenerative medicine
por: Caneparo, Christophe, et al.
Publicado: (2021)

Sunscreen products: Rationale for use, formulation development and regulatory considerations
por: Geoffrey, Kiriiri, et al.
Publicado: (2019)

Does the FDA have regulatory authority over adult autologous stem cell therapies? 21 CFR 1271 and the emperor's new clothes
por: Freeman, Michael, et al.
Publicado: (2012)

Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells‐based therapy product
por: Jha, Balendu Shekhar, et al.
Publicado: (2020)

Additively manufactured medical products – the FDA perspective
por: Di Prima, Matthew, et al.
Publicado: (2016)

An expanding horizon of complex injectable products: development and regulatory considerations
por: Panchal, Kanan, et al.
Publicado: (2022)

Regulatory considerations for generic products of non-biological complex drugs
por: Liu, Yu-Hsuan, et al.
Publicado: (2023)

Regulatory, safety and economic considerations of over-the-counter medicines in the Indian population
por: Narang, Prashant, et al.
Publicado: (2023)

Statistical and regulatory considerations in assessments of interchangeability of biological drug products
por: Tóthfalusi, Lászlo, et al.
Publicado: (2014)

 Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan 
por: Halioua-Haubold, Celine-Lea, et al.
Publicado: (2017)

Regulatory considerations to keep pace with innovation in digital health products
por: Torous, John, et al.
Publicado: (2022)

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective
por: Murphy, Ravindhi, et al.
Publicado: (2023)

[60]Fullerene for Medicinal Purposes, A Purity Criterion towards Regulatory Considerations
por: Keykhosravi, Sanaz, et al.
Publicado: (2019)

Data visualization explorer: A tool for participant representation in pivotal trials of FDA-approved medicinal products
por: Carmeli, Ariel B., et al.
Publicado: (2023)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

FDA perspectives on potential microarray-based clinical diagnostics
por: Težak, Živana, et al.
Publicado: (2006)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
por: Osman, Amira, et al.
Publicado: (2018)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2g4avias6fkfol30tl91ra6mfg